What is Eligo Bioscience?
Eligo Bioscience is a pioneering biotechnology firm specializing in in vivo gene editing technologies that target the microbiome. Their proprietary GEM (Gene Editing of the Microbiome) platform is designed to precisely edit the bacterial gene repertoire within the body, addressing diseases with high unmet medical needs. Founded and led by distinguished scientists, Eligo Bioscience is poised to revolutionize healthcare by offering novel therapeutic approaches through precise bacterial gene modification.
How much funding has Eligo Bioscience raised?
Eligo Bioscience has raised a total of $55M across 3 funding rounds:
Series A
$20M
Series B
$30M
Grant
$5M
Series A (2017): $20M with participation from Seventure Partners and Khosla Ventures
Series B (2023): $30M led by Khosla Ventures, Bpifrance, Seventure Partners, and Sanofi Ventures
Grant (2025): $5M supported by Ministry for Europe and Foreign Affairs
Key Investors in Eligo Bioscience
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies. The firm was founded in 2004 by Vinod Khosla, co-founder of Sun Microsystems. With over fourteen billion dollars under management, the firm focuses on a broad range of areas including consumer, enterprise, ai, fintech and financial services, semiconductors, health, agriculture/food, sustainable energy, and robotics.
Bpifrance
Founded in 2012, based out of France, Bpifrance finances companies - at each stage of their development - with credit, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and an acceleration program for startups, SMEs and mid-cap companies are also part of the offer for entrepreneurs.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofi's business footprint, and digital health solutions. Find out more: www.sanofiventures.com.
What's next for Eligo Bioscience?
With the recent influx of major strategic investment, Eligo Bioscience is well-positioned to advance its research and development pipeline. The company's focus on in vivo gene editing for microbiome-related diseases suggests a strategic expansion into therapeutic areas such as inflammatory bowel disease, metabolic disorders, and infectious diseases. Future growth will likely involve further clinical validation of their GEM platform and potential partnerships to bring their groundbreaking technologies to market, solidifying their role as a leader in precision microbiome therapeutics.
See full Eligo Bioscience company page
